Sabine A. Schaedelin

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 154 publications

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

Journal: JAMA neurology

Published: August 03, 2026

Anti-CD20 B cell depletion is associated with elevated mucosal-originating circulating regulatory IgA B cells in multiple sclerosis.

Anti-CD20 B cell depletion is associated with elevated mucosal-originating circulating regulatory IgA B cells in multiple sclerosis.

Journal: Science translational medicine

Published: July 22, 2026

Time course of motor recovery after stroke with and without levodopa: a post hoc 6-month longitudinal analysis of the ESTREL trial.

Time course of motor recovery after stroke with and without levodopa: a post hoc 6-month longitudinal analysis of the ESTREL trial.

Journal: European stroke journal

Published: May 15, 2026

Serum Glial Fibrillary Acidic Protein and Retinal Neuronal Loss as Additive Prognostic Markers of Disability in Multiple Sclerosis.

Serum Glial Fibrillary Acidic Protein and Retinal Neuronal Loss as Additive Prognostic Markers of Disability in Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: May 13, 2026

Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and Beyond.

Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and Beyond.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: April 23, 2026

Multi-compartment Myelin Streamline Decomposition reveals tract-specific and global brain network myelination in Multiple Sclerosis.

Multi-compartment Myelin Streamline Decomposition reveals tract-specific and global brain network myelination in Multiple Sclerosis.

Journal: Neuroimage. Reports

Published: February 25, 2026

Proinflammatory Epstein-Barr Virus Antibody Functions Track with Disease Activity in Multiple Sclerosis.

Proinflammatory Epstein-Barr Virus Antibody Functions Track with Disease Activity in Multiple Sclerosis.

Journal: Annals of neurology

Published: January 13, 2026

ESTREL-Fatigue-association of levodopa with post-stroke fatigue.

ESTREL-Fatigue-association of levodopa with post-stroke fatigue.

Journal: European stroke journal

Published: January 08, 2026

Sex differences in the development, treatment, and prognosis of multiple sclerosis in Switzerland.

Sex differences in the development, treatment, and prognosis of multiple sclerosis in Switzerland.

Journal: Frontiers in neuroscience

Published: November 13, 2025

Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controls.

Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controls.

Journal: Clinical chemistry and laboratory medicine

Published: November 08, 2025

Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity.

Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: November 05, 2025

The impact of levodopa on post-stroke depression: the ESTREL-depression-study.

The impact of levodopa on post-stroke depression: the ESTREL-depression-study.

Journal: European stroke journal

Published: October 29, 2025

Showing 1-12 of 154

Last Updated: 09/26/2026